• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Standard BioTools Inc. (Amendment)

    3/20/24 6:05:25 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $LAB alert in real time by email
    SC 13G/A 1 sayw24032001_13ga.htm


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-
    1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2
    UNDER THE SECURITIES EXCHANGE ACT OF 1934*

    (Amendment No. 1)

    Standard BioTools Inc.
    (Name of Issuer)

    Common stock, $0.001 par value per share
    (Title of Class of Securities)

    34385P108
    (CUSIP Number)

    March 18, 2024
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:


    ☐
    Rule 13d-1(b)

    ☒
    Rule 13d-1(c)

    ☐
    Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. 34385P108
    13G
    Page 2 of 22 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Investors LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    58,651,170*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    58,651,170*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    58,651,170*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    15.3%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    *
    See Item 4


    CUSIP No. 34385P108
    13G
    Page 3 of 22 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities Parent GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    58,651,170*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    58,651,170*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    58,651,170*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    15.3%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    *
    See Item 4


    CUSIP No. 34385P108
    13G
    Page 4 of 22 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    39,296,310*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    39,296,310*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    39,296,310*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    10.3%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    *
    See Item 4


    CUSIP No. 34385P108
    13G
    Page 5 of 22 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities Portfolio GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    39,296,310*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    39,296,310*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    39,296,310*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    10.3%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    *
    See Item 4


    CUSIP No. 34385P108
    13G
    Page 6 of 22 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities Illiquid Investments Sub-Master LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    39,296,310*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    39,296,310*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    39,296,310*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    10.3%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    *
    See Item 4


    CUSIP No. 34385P108
    13G
    Page 7 of 22 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities Drawdown GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    19,354,860*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    19,354,860*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    19,354,860*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    5.1%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    *
    See Item 4


    CUSIP No. 34385P108
    13G
    Page 8 of 22 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities Drawdown Portfolio GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    19,354,860*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    19,354,860*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    19,354,860*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    5.1%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    *
    See Item 4


    CUSIP No. 34385P108
    13G
    Page 9 of 22 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities Drawdown (Aggregator) LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    19,354,860*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    19,354,860*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    19,354,860*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    5.1%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    *
    See Item 4


    CUSIP No. 34385P108
    13G
    Page 10 of 22 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    O. Andreas Halvorsen
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Norway
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    58,651,170*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    58,651,170*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    58,651,170*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    15.3%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     

    *
    See Item 4


    CUSIP No. 34385P108
    13G
    Page 11 of 22 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    David C. Ott
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    58,651,170*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    58,651,170*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    58,651,170*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    15.3%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     

    *
    See Item 4


    CUSIP No. 34385P108
    13G
    Page 12 of 22 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Rose S. Shabet
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    58,651,170*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    58,651,170*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    58,651,170*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    15.3%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     

    *
    See Item 4


    CUSIP No. 34385P108
    13G
    Page 13 of 22 Pages
    Item 1(a).
    Name of Issuer:

    Standard BioTools Inc. (the “Issuer”)

    Item 1(b).
    Address of Issuer’s Principal Executive Offices:

    2 Tower Place, Suite 2000, South San Francisco, CA 94080

    Item 2(a).
    Name of Person Filing:

    Viking Global Investors LP (“VGI”),
    Viking Global Opportunities Parent GP LLC (“Opportunities Parent”),
    Viking Global Opportunities GP LLC (“Opportunities GP”),
    Viking Global Opportunities Portfolio GP LLC (“Opportunities Portfolio GP”),
    Viking Global Opportunities Illiquid Investments Sub-Master LP (“VGOP”),
    Viking Global Opportunities Drawdown GP LLC (“VGOD GP”),
    Viking Global Opportunities Drawdown Portfolio GP LLC (“VGOD Portfolio GP”),
    Viking Global Opportunities Drawdown (Aggregator) LP (“VGOD”),
    O. Andreas Halvorsen, David C. Ott and Rose S. Shabet (collectively, the “Reporting Persons”).

    Item 2(b).
    Address of Principal Business Office or, if none, Residence:

    The business address of each of the Reporting Persons is: 600 Washington Boulevard, Floor 11, Stamford, Connecticut 06901.

    Item 2(c).
    Citizenship:

    VGI is a Delaware limited partnership; Opportunities Parent, Opportunities GP, Opportunities Portfolio GP, VGOD GP, and VGOD Portfolio GP are Delaware limited liability companies; VGOP and VGOD are Cayman Islands exempted limited partnerships; O. Andreas Halvorsen is a citizen of Norway; and David C. Ott and Rose S. Shabet are citizens of the United States.

    Item 2(d).
    Titles of Classes of Securities:

    Common stock, $0.001 par value per share (“Common Stock”)

    Item 2(e).
    CUSIP NUMBER: 34385P108

    CUSIP No. 34385P108
    13G
    Page 14 of 22 Pages
    Item 3.
    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     
    (a)
    ☐ Broker or dealer registered under Section 15 of the Exchange Act
     
    (b)
    ☐ Bank as defined in Section 3(a)(6) of the Exchange Act
     
    (c)
    ☐ Insurance company as defined in Section 3(a)(19) of the Exchange Act
     
    (d)
    ☐ Investment company registered under Section 8 of the Investment Company Act of 1940
     
    (e)
    ☐ Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940: see Rule 13d-1(b)(1)(ii)(E)
     
    (f)
    ☐ Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund; see Rule 13d-1(b)(1)(ii)(F)
     
    (g)
    ☐ Parent holding company, in accordance with Rule 13d-1(b)(1)(ii)(G).
     
    (h)
    ☐ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act.
     
    (i)
    ☐ Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940.
     
    (j)
    ☐ Non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
     
    (k)
    ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

    Item 4.
    Ownership:

    The percentages set forth herein are calculated based on 382,461,253 shares of Common Stock outstanding as of March 18, 2024, as provided by the Issuer.

     
    A.
    VGI

     
    (a)
    Amount beneficially owned: 58,651,170

     
    (b)
    Percent of Class: 15.3%

     
    (c)
    Number of shares as to which such person has:

     
    (i)
    Sole power to vote or to direct the vote: 0

     
    (ii)
    Shared power to vote or to direct the vote: 58,651,170

     
    (iii)
    Sole power to dispose or to direct the disposition of: 0

     
    (iv)
    Shared power to dispose or to direct the disposition of: 58,651,170

    CUSIP No. 34385P108
    13G
    Page 15 of 22 Pages

    VGI provides managerial services to VGOP and VGOD. VGI has the authority to dispose of and vote the shares of Common Stock that VGOP and VGOD directly own. VGI does not directly own any shares of Common Stock.

    Based on Rule 13d-3 of the Act, VGI may be deemed to beneficially own the shares of Common Stock that VGOP and VGOD directly own.

    VGI beneficially owns 58,651,170 shares of Common Stock consisting of (i) 39,296,310 shares of Common Stock directly owned by VGOP and (ii) 19,354,860 shares of Common Stock directly owned by VGOD.

     
    B.
    Opportunities Parent

     
    (a)
    Amount beneficially owned: 58,651,170

     
    (b)
    Percent of Class: 15.3%

     
    (c)
    Number of shares as to which such person has:

     
    (i)
    Sole power to vote or to direct the vote: 0

     
    (ii)
    Shared power to vote or to direct the vote: 58,651,170

     
    (iii)
    Sole power to dispose or to direct the disposition of: 0

     
    (iv)
    Shared power to dispose or to direct the disposition of: 58,651,170

    Opportunities Parent is the sole member of Opportunities GP, which has the authority to dispose of and vote the shares of Common Stock controlled by Opportunities Portfolio GP (which consists of the shares of Common Stock that VGOP directly owns) and is the sole member of VGOD GP, which has the authority to dispose of and vote the shares of Common Stock controlled by VGOD Portfolio GP (which consists of the shares of Common Stock that VGOD directly owns). Opportunities Parent does not directly own any shares of Common Stock.
     
    Based on Rule 13d-3 of the Act, Opportunities Parent may be deemed to beneficially own the shares of Common Stock that VGOP and VGOD directly own.

    Opportunities Parent beneficially owns 58,651,170 shares of Common Stock consisting of (i) 39,296,310 shares of Common Stock directly owned by VGOP and (ii) 19,354,860 shares of Common Stock directly owned by VGOD.

    CUSIP No. 34385P108
    13G
    Page 16 of 22 Pages
     
    C.
    Opportunities GP

     
    (a)
    Amount beneficially owned: 39,296,310

     
    (b)
    Percent of Class: 10.3%

     
    (c)
    Number of shares as to which such person has:

     
    (i)
    Sole power to vote or to direct the vote: 0

     
    (ii)
    Shared power to vote or to direct the vote: 39,296,310

     
    (iii)
    Sole power to dispose or to direct the disposition of: 0

     
    (iv)
    Shared power to dispose or to direct the disposition of: 39,296,310

    Opportunities GP serves as the sole member of Opportunities Portfolio GP and has the authority to dispose of and vote the shares of Common Stock controlled by Opportunities Portfolio GP, which consists of the shares of Common Stock that VGOP directly owns. In addition, Opportunities GP is the general partner of each of Viking Global Opportunities Intermediate LP, Viking Global Opportunities III LP, and Viking Global Opportunities LP. Opportunities GP does not directly own any shares of Common Stock.

    Based on Rule 13d-3 of the Act, Opportunities GP may be deemed to beneficially own the shares of Common Stock that VGOP directly owns.

    Opportunities GP beneficially owns 39,296,310 shares of Common Stock consisting of 39,296,310 shares of Common Stock directly owned by VGOP.

     
    D.
    Opportunities Portfolio GP

     
    (a)
    Amount beneficially owned: 39,296,310

     
    (b)
    Percent of Class: 10.3%

     
    (c)
    Number of shares as to which such person has:

     
    (i)
    Sole power to vote or to direct the vote: 0

     
    (ii)
    Shared power to vote or to direct the vote: 39,296,310

     
    (iii)
    Sole power to dispose or to direct the disposition of: 0

     
    (iv)
    Shared power to dispose or to direct the disposition of: 39,296,310

    Opportunities Portfolio GP serves as the general partner of VGOP and has the authority to dispose of and vote the shares of Common Stock that VGOP directly owns. Opportunities Portfolio GP does not directly own any shares of Common Stock.

    Based on Rule 13d-3 of the Act, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock that VGOP directly owns.

    Opportunities Portfolio GP beneficially owns 39,296,310 shares of Common Stock consisting of 39,296,310 shares of Common Stock directly owned by VGOP.

    CUSIP No. 34385P108
    13G
    Page 17 of 22 Pages
     
    E.
    VGOP

     
    (a)
    Amount beneficially owned: 39,296,310

     
    (b)
    Percent of Class: 10.3%

     
    (c)
    Number of shares as to which such person has:

     
    (i)
    Sole power to vote or to direct the vote: 0

     
    (ii)
    Shared power to vote or to direct the vote: 39,296,310

     
    (iii)
    Sole power to dispose or to direct the disposition of: 0

     
    (iv)
    Shared power to dispose or to direct the disposition of: 39,296,310

    VGOP has the authority to dispose of and vote the shares of Common Stock that it directly owns, which power may be exercised by its general partner, Opportunities Portfolio GP, and by VGI, an affiliate of Opportunities Portfolio GP, which provides managerial services to VGOP.

    Viking Global Opportunities LP (a Delaware limited partnership) and Viking Global Opportunities III LP (a Cayman Islands exempted limited partnership), through its investment in Viking Global Opportunities Intermediate LP (a Cayman Islands exempted limited partnership), invest substantially all of their assets in Viking Global Opportunities Master LP (a Cayman Islands exempted limited partnership), which in turn invests through VGOP.

     
    F.
    VGOD GP

     
    (a)
    Amount beneficially owned: 19,354,860

     
    (b)
    Percent of Class: 5.1%

     
    (c)
    Number of shares as to which such person has:

     
    (i)
    Sole power to vote or to direct the vote: 0

     
    (ii)
    Shared power to vote or to direct the vote: 19,354,860

     
    (iii)
    Sole power to dispose or to direct the disposition of: 0
     
     
    (iv)
    Shared power to dispose or to direct the disposition of: 19,354,860

    VGOD GP serves as the sole member of VGOD Portfolio GP and has the authority to dispose of and vote the shares of Common Stock controlled by VGOD Portfolio GP, which consists of the shares of Common Stock that VGOD directly owns. In addition, VGOD GP is the general partner of each of Viking Global Opportunities (Internal) LP, Viking Global Opportunities Drawdown (Onshore) LP, and Viking Global Opportunities Drawdown (Offshore) LP. VGOD GP does not directly own any shares of Common Stock.
     
    Based on Rule 13d-3 of the Act, VGOD GP may be deemed to beneficially own the shares of Common Stock that VGOD directly owns.
     
    VGOD GP beneficially owns 19,354,860 shares of Common Stock consisting of 19,354,860 shares of Common Stock directly owned by VGOD.

    CUSIP No. 34385P108
    13G
    Page 18 of 22 Pages
     
    G.
    VGOD Portfolio GP

     
    (a)
    Amount beneficially owned: 19,354,860

     
    (b)
    Percent of Class: 5.1%

     
    (c)
    Number of shares as to which such person has:

     
    (i)
    Sole power to vote or to direct the vote: 0

     
    (ii)
    Shared power to vote or to direct the vote: 19,354,860

     
    (iii)
    Sole power to dispose or to direct the disposition of: 0

     
    (iv)
    Shared power to dispose or to direct the disposition of: 19,354,860

    VGOD Portfolio GP serves as the general partner of VGOD and has the authority to dispose of and vote the shares of Common Stock that VGOD directly owns. VGOD Portfolio GP does not directly own any shares of Common Stock.
     
    Based on Rule 13d-3 of the Act, VGOD Portfolio GP may be deemed to beneficially own the shares of Common Stock that VGOD directly owns.
     
    VGOD Portfolio GP beneficially owns 19,354,860 shares of Common Stock consisting of 19,354,860 shares of Common Stock directly owned by VGOD.
     
     
    H.
    VGOD

     
    (a)
    Amount beneficially owned: 19,354,860

     
    (b)
    Percent of Class: 5.1%

     
    (c)
    Number of shares as to which such person has:

     
    (i)
    Sole power to vote or to direct the vote: 0

     
    (ii)
    Shared power to vote or to direct the vote: 19,354,860

     
    (iii)
    Sole power to dispose or to direct the disposition of: 0

     
    (iv)
    Shared power to dispose or to direct the disposition of: 19,354,860

    VGOD has the authority to dispose of and vote the shares of Common Stock that it directly owns, which power may be exercised by its general partner, VGOD Portfolio GP, and by VGI, an affiliate of VGOD Portfolio GP, which provides managerial services to VGOD.
     
    Viking Global Opportunities Drawdown (Offshore) LP (a Cayman Islands exempted limited partnership) and Viking Global Opportunities Drawdown (Internal) LP (a Delaware limited partnership), through its investment in Viking Global Opportunities Drawdown (Onshore) LP (a Delaware limited partnership), invest substantially all of their assets in VGOD.

    CUSIP No. 34385P108
    13G
    Page 19 of 22 Pages
       
    I.
    O. Andreas Halvorsen, David C. Ott and Rose S. Shabet

     
    (a)
    Amount beneficially owned: 58,651,170

     
    (b)
    Percent of Class: 15.3%

     
    (c)
    Number of shares as to which such person has:
     
     
    (i)
    Sole power to vote or to direct the vote: 0
     
     
    (ii)
    Shared power to vote or to direct the vote: 58,651,170
     
     
    (iii)
    Sole power to dispose or to direct the disposition of: 0
     
     
    (iv)
    Shared power to dispose or to direct the disposition of: 58,651,170
     
    Mr. Halvorsen, Mr. Ott and Ms. Shabet, as Executive Committee Members of Viking Global Partners LLC (general partner of VGI) and Opportunities Parent, have shared authority to dispose of and vote the shares of Common Stock beneficially owned by VGI and Opportunities Parent. None of Mr. Halvorsen, Mr. Ott and Ms. Shabet directly owns any shares of Common Stock.
     
    Based on Rule 13d-3 of the Act, each may be deemed to beneficially own the shares of Common Stock that VGOP and VGOD directly own.
     
    Mr. Halvorsen, Mr. Ott and Ms. Shabet each beneficially own 58,651,170 shares of Common Stock consisting of (i) 39,296,310 shares of Common Stock directly owned by VGOP and (ii) 19,354,860 shares of Common Stock directly owned by VGOD.

    Item 5.
    Ownership of Five Percent or Less of a Class.
     
    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following ☐
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
     
    The response to Item 4 is incorporated by reference herein.
     

    CUSIP No. 34385P108
    13G
    Page 20 of 22 Pages

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
     
    Not applicable.
     
    Item 8.
    Identification and Classification of Members of the Group.
     
    Not applicable.
     
    Item 9.
    Notice of Dissolution of Group.
     
    Not applicable.

    Item 10.
    Certification. (if filing pursuant to Rule 13d-1(c))
     
    By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    CUSIP No. 34385P108
    13G
    Page 21 of 22 Pages
    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    Dated: March 20, 2024

     
    By:
    /s/ Scott M. Hendler
     
    Name:
    Scott M. Hendler on behalf of O. Andreas Halvorsen (1)
       
     
    By:
    /s/ Scott M. Hendler
     
    Name:
    Scott M. Hendler on behalf of David C. Ott (2)
       
     
    By:
    /s/ Scott M. Hendler
     
    Name:
    Scott M. Hendler on behalf of Rose S. Shabet (3)

    (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).

    (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).

    (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).


    CUSIP No. 34385P108
    13G
    Page 22 of 22 Pages
    EXHIBIT A - JOINT FILING AGREEMENT

    This joint filing agreement is made and entered into as of this 20th day of March, 2024, by and among Viking Global Investors LP, Viking Global Opportunities Parent GP LLC, Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP, Viking Global Opportunities Drawdown GP LLC, Viking Global Opportunities Drawdown Portfolio GP LLC, Viking Global Opportunities Drawdown (Aggregator) LP, O. Andreas Halvorsen, David C. Ott and Rose S. Shabet.

    The parties to this Agreement hereby agree to prepare jointly and file timely (and otherwise to deliver as appropriate) all filings on any Forms 3, 4, or 5 or Schedules 13D or 13G, and any and all amendments thereto and any other documents relating thereto (collectively, the “Filings”) as required to be filed pursuant to the Securities Exchange Act of 1934, as amended. The parties to this Agreement further agree and covenant that each will fully cooperate with such other parties in the preparation, timely filing, and delivery of all such Filings.

    IN WITNESS WHEREOF, the parties hereto have executed this agreement as of the date first set forth above.

    Dated: March 20, 2024

     
    By:
    /s/ Scott M. Hendler
     
    Name:
    Scott M. Hendler on behalf of O. Andreas Halvorsen (1)
       
     
    By:
    /s/ Scott M. Hendler
     
    Name:
    Scott M. Hendler on behalf of David C. Ott (2)
       
     
    By:
    /s/ Scott M. Hendler
     
    Name:
    Scott M. Hendler on behalf of Rose S. Shabet (3)

    (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).

    (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).

    (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).



    Get the next $LAB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LAB

    DatePrice TargetRatingAnalyst
    2/27/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    4/16/2024$3.50Buy
    TD Cowen
    4/4/2024$3.25Buy
    Jefferies
    7/12/2023$4.00Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $LAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Standard BioTools downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded Standard BioTools from Overweight to Sector Weight

      2/27/25 6:22:46 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • TD Cowen initiated coverage on Standard BioTools with a new price target

      TD Cowen initiated coverage of Standard BioTools with a rating of Buy and set a new price target of $3.50

      4/16/24 8:09:43 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Jefferies initiated coverage on Standard BioTools with a new price target

      Jefferies initiated coverage of Standard BioTools with a rating of Buy and set a new price target of $3.25

      4/4/24 7:41:52 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    SEC Filings

    See more
    • Standard BioTools Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)

      6/23/25 9:11:17 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Standard BioTools Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)

      6/20/25 4:16:03 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SD filed by Standard BioTools Inc.

      SD - STANDARD BIOTOOLS INC. (0001162194) (Filer)

      6/2/25 4:06:54 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

      Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumina and SomaLogic have partnered in proteomics co-development since late 2021 SAN DIEGO, June 23, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today it has entered into a definitive agreement with Standard BioTools (NASDAQ:LAB) under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milesto

      6/23/25 7:13:00 AM ET
      $ILMN
      $LAB
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina

      Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash   Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single SOMAmer Reagent Business   Simplifies Operating Structure and Enables Achievement of Adjusted EBITDA Break-Even    Cash & Cash Equivalents of At Least $550 Million Expected at Close to Fuel Inorganic Growth Strategy and Drive Long-Term Value Creation SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced the strategic sale of SomaLogic to Illumina, Inc. (NASDAQ:ILMN) ("Illumina"), including Soma

      6/23/25 7:05:18 AM ET
      $ILMN
      $LAB
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Standard BioTools to Host Inaugural "Proteomics Roundtable" Webcast Series

      SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced the launch of its inaugural Proteomics Roundtable Series – a program of virtual events designed to spark conversation about the rapidly evolving field of proteomics. The series will spotlight thought leaders and industry experts discussing groundbreaking research, technological advancements and real-world applications of proteomics shaping the future of healthcare. The first session will be: Is More Really More? Evaluating the Case for High-Plex, High-Quality ProteomicsFriday, June 6, 2025 – 11:00 am ET Stephen Williams, MD, PhD, Chief Medical Officer at Standard BioTools wi

      5/30/25 7:00:00 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Casdin Partners Master Fund, L.P. disposed of $580,425 worth of shares (545,000 units at $1.06), was granted 58,215 shares, bought $5,134,321 worth of shares (4,820,959 units at $1.06) and acquired $580,425 worth of shares (545,000 units at $1.06) (SEC Form 4)

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      3/4/25 8:19:51 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Casdin Partners Master Fund, L.P. bought $546,750 worth of shares (250,000 units at $2.19) (SEC Form 4)

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      8/29/24 8:30:41 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Casdin Partners Master Fund, L.P. bought $1,546,237 worth of shares (750,000 units at $2.06) (SEC Form 4)

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      8/26/24 8:10:10 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    Leadership Updates

    Live Leadership Updates

    See more
    • Standard BioTools Appoints Alex Kim as Chief Financial Officer

      SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools' finance organization. Michael Egholm, President and Chief Executive Officer of Standard BioTools, said, "I am thrilled to announce Alex as our next CFO. Having co-founded Standard BioTools with me, Alex's deep understan

      11/7/24 8:00:00 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

      Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

      12/12/23 5:31:00 PM ET
      $EXAS
      $ILMN
      $LAB
      $ME
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Standard BioTools Appoints Jeffrey Black as Chief Financial Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      Industry veteran Jeffrey Black brings 30 years of financial and operating leadership experience Vikram Jog to become Special Advisor for transition period SOUTH SAN FRANCISCO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced the appointment of Jeffrey Black as Senior Vice President and Chief Financial Officer effective today. Black will lead Standard BioTools' finance, accounting and investor relations functions, reporting to Michael Egholm, Ph.D., President and Chief Executive Officer. Vikram Jog will remain at the company for a period as Special Advisor to th

      5/15/23 7:30:14 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

      SC 13G/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

      11/14/24 3:32:10 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

      SC 13G/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

      11/12/24 6:01:47 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

      SC 13G/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

      11/4/24 1:59:57 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    Financials

    Live finance-specific insights

    See more
    • Standard BioTools Reports First Quarter 2025 Financial Results

      SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the first quarter ended March 31, 2025. Recent Highlights: First quarter 2025 revenue of $40.8 million45% reduction in operating loss and 29% improvement in adjusted EBITDA year-over-yearOperationalized $10 million more in annual run rate cost reductions, totaling $90 million since merger Strong balance sheet with $261 million in cash & cash equivalents and no material debt as of March 31, 2025 "Standard BioTools delivered a solid first quarter in line with our expectations, reflecting focused execution in a

      5/6/25 4:01:00 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025

      SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webcast will be available online on the Investor Relations page of the Company's website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investor R

      4/22/25 7:00:00 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results

      SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the fourth quarter and fiscal year ended December 31, 2024. Recent Highlights: Full Year 2024 pro forma combined revenue of $175.1 million17% Full Year reduction in pro forma operating loss and 33% year over year improvement in adjusted EBITDA Additional $10 million in operational cost reductions, now totaling $90 million in synergies over 12 monthsStrong Balance sheet with $295 million in cash, cash equivalents, restricted cash, short-term investments and no material debt at year end 2024 expected to provide suffi

      2/26/25 4:01:00 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cox Troy was granted 94,592 shares, increasing direct ownership by 58% to 256,412 units (SEC Form 4)

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      6/24/25 7:00:22 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Eloi Fenel M was granted 94,592 shares, increasing direct ownership by 67% to 236,183 units (SEC Form 4)

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      6/24/25 6:58:52 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Carey Thomas D. was granted 94,592 shares, increasing direct ownership by 95% to 194,058 units (SEC Form 4)

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      6/24/25 6:58:06 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials